Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are o...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266636432400105X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136504757256192 |
|---|---|
| author | Sabine Schmid, MD Lisa Holer, MSc Katrin Gysel, MSc Kira-Lee Koster, MD Sacha I. Rothschild, MD Laura A. Boos, MD Lorenz Frehner, MD Sabine Cardoso Almeida, MD Christian Britschgi, MD, PhD Yannis Metaxas, MD Michael Mark, MD Patrizia Froesch, MD Wolf-Dieter Janthur, MD Anna Allemann, MD Christine Waibel, MD Catherine Von der Mühll-Schill, MD Martin Früh, MD Laetitia A. Mauti, MD, PhD |
| author_facet | Sabine Schmid, MD Lisa Holer, MSc Katrin Gysel, MSc Kira-Lee Koster, MD Sacha I. Rothschild, MD Laura A. Boos, MD Lorenz Frehner, MD Sabine Cardoso Almeida, MD Christian Britschgi, MD, PhD Yannis Metaxas, MD Michael Mark, MD Patrizia Froesch, MD Wolf-Dieter Janthur, MD Anna Allemann, MD Christine Waibel, MD Catherine Von der Mühll-Schill, MD Martin Früh, MD Laetitia A. Mauti, MD, PhD |
| author_sort | Sabine Schmid, MD |
| collection | DOAJ |
| description | Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on the basis of MAPS2 results. Here we report on real-world survival and safety outcomes of ipi-nivo for patients with MPM in Switzerland. Methods: Twelve cancer centers contributed data to this retrospective cohort. Baseline characteristics including age, sex, histology, programmed death-ligand 1 expression, Eastern Cooperative Oncology Group performance status (ECOG PS), and previous/subsequent therapies were collected. The efficacy and safety outcomes were assessed by local investigators. Results: Of the 109 patients with MPM treated with ipi-nivo between November 2017 and March 2023 (median follow-up of 16.6 months) 75% had epithelioid, 9% biphasic, and 16% sarcomatoid histology. The median age was 72 years; 91% were males, and 83% had an ECOG PS of 0 to 1. Ipilimumab in combination with nivolumab was given as 1L in 43% and as 2L+ treatment in 57% of patients. The objective response rate was 21% in 1L and 15% in 2L+. Median progression-free survival was 6.5 and 2.8 months, respectively. Median overall survival (OS) from the start of ipi-nivo was 12.6 months for 1L and 6.9 months for 2L+. No differences in OS were observed depending on age and programmed death-ligand 1 expression. Nevertheless, the median OS was significantly worse in patients with an ECOG PS of 2 or higher than those with an ECOG PS of 0 to 1 (2.4 versus 11.9 months, p < 0.001). Treatment-related adverse events (TRAEs) of any grade related to ipi-nivo treatment occurred in 65 patients (62%). The highest-grade TRAE was 1 to 2 in 58% of these patients and 3 or higher in 42% Treatment discontinuation due to a TRAE occurred in 22% of patients. Conclusion: In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar. |
| format | Article |
| id | doaj-art-eaf1ac72cdcf42a0a92d67407c36e4ea |
| institution | Kabale University |
| issn | 2666-3643 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-eaf1ac72cdcf42a0a92d67407c36e4ea2024-12-09T04:28:07ZengElsevierJTO Clinical and Research Reports2666-36432024-12-01512100735Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line TreatmentSabine Schmid, MD0Lisa Holer, MSc1Katrin Gysel, MSc2Kira-Lee Koster, MD3Sacha I. Rothschild, MD4Laura A. Boos, MD5Lorenz Frehner, MD6Sabine Cardoso Almeida, MD7Christian Britschgi, MD, PhD8Yannis Metaxas, MD9Michael Mark, MD10Patrizia Froesch, MD11Wolf-Dieter Janthur, MD12Anna Allemann, MD13Christine Waibel, MD14Catherine Von der Mühll-Schill, MD15Martin Früh, MD16Laetitia A. Mauti, MD, PhD17Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Corresponding author. Address for correspondence: Sabine Schmid, MD, Department of Medical Oncology Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.Swiss Group for Clinical Cancer Research (SAKK), Bern, SwitzerlandSwiss Group for Clinical Cancer Research (SAKK), Bern, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, SwitzerlandDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland; Department of Oncology/Hematology, Cantonal Hospital Baden, Baden, SwitzerlandDepartment of Medical Oncology and Hematology, University Hospital Zürich, Zürich, SwitzerlandDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, SwitzerlandDepartment of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland; Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, SwitzerlandDepartment of Medical Oncology, Cantonal Hospital Münsterlingen, Münsterlingen, SwitzerlandDepartment of Medical Oncology, Cantonal Hospital Chur, Chur, Switzerland; Università della Svizzera Italiana, Lugano, SwitzerlandDepartment of Medical Oncology, Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale, Bellinzona, SwitzerlandDepartment of Medical Oncology, Cantonal Hospital Aarau, Aarau, SwitzerlandDepartment of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, SwitzerlandDepartment of Oncology/Hematology, Cantonal Hospital Baden, Baden, SwitzerlandDepartment of Medical Oncology, Claraspital Basel, Basel, SwitzerlandDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, SwitzerlandDepartment of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, SwitzerlandObjectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on the basis of MAPS2 results. Here we report on real-world survival and safety outcomes of ipi-nivo for patients with MPM in Switzerland. Methods: Twelve cancer centers contributed data to this retrospective cohort. Baseline characteristics including age, sex, histology, programmed death-ligand 1 expression, Eastern Cooperative Oncology Group performance status (ECOG PS), and previous/subsequent therapies were collected. The efficacy and safety outcomes were assessed by local investigators. Results: Of the 109 patients with MPM treated with ipi-nivo between November 2017 and March 2023 (median follow-up of 16.6 months) 75% had epithelioid, 9% biphasic, and 16% sarcomatoid histology. The median age was 72 years; 91% were males, and 83% had an ECOG PS of 0 to 1. Ipilimumab in combination with nivolumab was given as 1L in 43% and as 2L+ treatment in 57% of patients. The objective response rate was 21% in 1L and 15% in 2L+. Median progression-free survival was 6.5 and 2.8 months, respectively. Median overall survival (OS) from the start of ipi-nivo was 12.6 months for 1L and 6.9 months for 2L+. No differences in OS were observed depending on age and programmed death-ligand 1 expression. Nevertheless, the median OS was significantly worse in patients with an ECOG PS of 2 or higher than those with an ECOG PS of 0 to 1 (2.4 versus 11.9 months, p < 0.001). Treatment-related adverse events (TRAEs) of any grade related to ipi-nivo treatment occurred in 65 patients (62%). The highest-grade TRAE was 1 to 2 in 58% of these patients and 3 or higher in 42% Treatment discontinuation due to a TRAE occurred in 22% of patients. Conclusion: In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar.http://www.sciencedirect.com/science/article/pii/S266636432400105XMalignant pleural mesotheliomaIpilimumabNivolumabReal-worldOutcome |
| spellingShingle | Sabine Schmid, MD Lisa Holer, MSc Katrin Gysel, MSc Kira-Lee Koster, MD Sacha I. Rothschild, MD Laura A. Boos, MD Lorenz Frehner, MD Sabine Cardoso Almeida, MD Christian Britschgi, MD, PhD Yannis Metaxas, MD Michael Mark, MD Patrizia Froesch, MD Wolf-Dieter Janthur, MD Anna Allemann, MD Christine Waibel, MD Catherine Von der Mühll-Schill, MD Martin Früh, MD Laetitia A. Mauti, MD, PhD Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment JTO Clinical and Research Reports Malignant pleural mesothelioma Ipilimumab Nivolumab Real-world Outcome |
| title | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment |
| title_full | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment |
| title_fullStr | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment |
| title_full_unstemmed | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment |
| title_short | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment |
| title_sort | real world outcomes of patients with malignant pleural mesothelioma receiving a combination of ipilimumab and nivolumab as first or later line treatment |
| topic | Malignant pleural mesothelioma Ipilimumab Nivolumab Real-world Outcome |
| url | http://www.sciencedirect.com/science/article/pii/S266636432400105X |
| work_keys_str_mv | AT sabineschmidmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT lisaholermsc realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT katringyselmsc realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT kiraleekostermd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT sachairothschildmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT lauraaboosmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT lorenzfrehnermd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT sabinecardosoalmeidamd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT christianbritschgimdphd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT yannismetaxasmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT michaelmarkmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT patriziafroeschmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT wolfdieterjanthurmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT annaallemannmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT christinewaibelmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT catherinevondermuhllschillmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT martinfruhmd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment AT laetitiaamautimdphd realworldoutcomesofpatientswithmalignantpleuralmesotheliomareceivingacombinationofipilimumabandnivolumabasfirstorlaterlinetreatment |